Sector News

Tessa buys Euchloe for suite of checkpoint inhibitors

March 23, 2017
Life sciences

Tessa Therapeutics has bought Euchloe Bio for its suite of checkpoint inhibitors. The takeover gives Tessa antibodies against PD-1, PD-L1, CTLA-4 and other targets that it sees complementing its own virus-specific T cells.

Euchloe spun out of A*STAR’s Singapore Immunology Network last year, only to be snapped up quickly by its compatriot Tessa. In its brief time as an independent company, Euchloe worked on getting checkpoint inhibitors targeting PD-1, PD-L1, CTLA-4, TIM-3 and LAG-3 ready for the clinic. The list covers established checkpoints targeted by Merck’s Keytruda and Bristol-Myers Squibb’s Yervoy, as well as emerging areas that have attracted the interest of Tesaro and others.

The pipeline programs are well behind the leaders in some of the niches. Euchloe will continue to develop its antibodies for use as monotherapies. But, with Tessa seeing the checkpoint inhibitors as a way to unlock the full power of its own pipeline, there is value in the acquired assets even if they never establish themselves as standalone products.

“Euchloe Bio’s strong expertise and extensive range of proprietary antibodies is an excellent complement to Tessa’s existing portfolio,” Tessa CSO John Connolly said in a statement. “The strong preclinical data we are seeing suggests that the combination of our technologies has strong potential to deliver further breakthroughs in cancer immunotherapy.”

Tessa’s own pipeline is built on technologies developed at Baylor College of Medicine, notably a virus-specific T cell platform. The company initially used the platform to orchestrate attacks by the immune system on tumors that express Epstein-Barr virus. That is the approach taken by Tessa’s phase 3 treatment for nasopharyngeal carcinoma.

More recently, Tessa has begun targeting tumors that express human papillomavirus. This led Tessa to step up its interest in immune checkpoint inhibitors. A phase 1 trial is assessing the combination of Tessa’s T cells and Bristol-Myers’ Opdivo. By acquiring Euchloe, Tessa has gained an in-house source of drugs to combine with its T cells.

Tessa also sees the acquisition benefiting another of its programs. The company had already begun working with Euchloe on CAR technologies prior to the buyout. Tessa thinks pairing its T cells with CAR targeting will enable it to hit solid tumors.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach